Global Proteomics Market Size, Share And Growth

(MENAFN- Straits Research) Proteomics is the study of the structure and function of proteins. On the other hand, proteinomics is more challenging to study because genomes do not change. On the other hand, proteins are dynamic and adaptable to the cells and environments in which they are examined. It has been significant growth in the global proteomics market over the last few years because of the increased utility of proteomics in diagnosing diseases and identifying new drugs for treatment. Proteomics is to blame for this surge in popularity. The market's growth is expected to be driven by factors such as a rise in the focus of key players on product development, an increase in the amount of R&D for proteomics, an increase in the popularity of personalized medicines, and technological advancements in proteomics. As a result of stringent regulatory approvals, expensive instruments, and a lack of qualified researchers, the market's growth is expected to be limited.
Market Dynamics
Growing Need for Personalized Medicines and Rising Proteomics Technology Drives the Global Market
To improve diagnosis and treatment and to detect disease at an earlier stage, personalized medicine is a multi-faceted approach in inpatient care. Another critical factor in the industry's growth is expanding the personalized medicine market. Personalized medicine develops a treatment strategy based on an individual patient's unique medical needs. It is widely used in various settings for the diagnosis and treatment of cancer. Proteomics is a new science that has the potential to make significant contributions to personalized medicine. Cell physiology's molecular machinery, such as protein expression and post-translational modification, isoforms, variations, and protein-protein complexes, are examined in detail. It has an advantage over genomics-based assays.
Proteomics' recent technological advancements are expected to be a driving force in the market's expansion. The ease of use of the instruments and the improved results of the procedures have piqued the interest of pharmaceutical and biotechnology companies in proteomics. The improved outcomes of these procedures have piqued people's curiosity. Increasing the resolution of mass spectrometry, for example, helps extract helpful information from a small amount of sample material through technological advancements like this. LC/MS, GC/MS, FT-MS, and MALDI-TOF/TOF are examples of dual mass analyzers that can provide additional information about protein structure. Small molecules and lipids could benefit from an order of magnitude or more sensitivity, thanks to the revolutionary MALDI-2 technology. The separation and identification of proteins have been greatly aided by developing new methods such as gel electrophoresis and improved liquid chromatography. Proteomics is expected to benefit significantly from these new developments in technology. Consequently, the impact of this driver will likely increase over the forecast period.
Growing Use of Biomarkers Create Tremendous Opportunities
The discovery and analysis of disease-specific biomarkers in conditions as diverse as cancer, neurological disorders, and cardiovascular diseases can increase insight into the workings of disease mechanisms. This increased understanding of drug interactions and effects on metabolic pathways allows for the development of new drugs. In searching for new clinical biomarkers to detect and diagnose cancer and other diseases early and discovering new therapeutic targets from readily available bio-specimens, proteomic technologies hold a significant amount of untapped potential. A relatively new proteomic method, called DIGE, is said to be effective for the molecular characterization of tumor development and the detection of tumor-specific biomarkers in oesophageal scans of cell cancer when combined with liquid chromatography and mass spectrometry (LC/MS). Because new biomarkers are discovered, the proteomics market has access to many new products.
Regional Analysis
North America is the highest revenue contributor growing with a CAGR of 11.1% during the forecast period. Because of the government organization's financial support, proteomics research in North America has significantly improved in recent years. The market experienced significant expansion due to substantial funding from various organizations and increased the number of agreements and collaborations implemented. Additionally, an increase in the amount invested in research and development is anticipated to help facilitate the expansion of the market. On the other hand, it is expected that recent regional economic tensions will harm the growth rate.
Europe is the second-largest contributor to the market and is estimated to reach around USD 20,854.96 million at a CAGR of 11.8% during the forecast period. Because of this, governments and federal departments in three major countries are investing in proteomics research and development. This contributes to the expansion of the market. In addition, the industry is seeing an increase in collaboration between smaller firms and larger suppliers and between firms and academic institutions. Increased demand for personalized medicine, advancements in technology, and bioinformatics in proteomics all contribute to the growth of Europe's proteomics market. Proteomics-specific labs and government funding are also contributing to the market's growth. Regulatory restrictions and high equipment costs hamper proteomics technology development.
Because of financial restraints, the rate of growth of the proteomics industry in the Asia-Pacific region has slowed down in recent years. Proteomics is widely used in the healthcare industry to detect and diagnose diseases due to increased investment in the field by companies based in other countries, even though its market share is relatively low. It is anticipated that the Asia-Pacific proteomics market will experience significant development due to an increase in technological innovations and a substantial increase in funding from both public and private organizations. It is anticipated that increased investment by businesses in research and development activities will propel market expansion.
LAMEA proteomics is expected to grow moderately shortly due to a lack of technological advances. But several businesses are putting their efforts into growing in the area. The market's growth is fueled by increased funding from federal and state governments. There is also expected to be a significant increase in the number of substantial players' collaborations, expansions, and product launches shortly.
Competitive Analysis
The key players in the global Proteomics
market included

Agilent Technologies Inc
Danaher Corporation
LI-COR, Inc
PerkinElmer, Inc
Thermo Fisher Scientific, Inc
HORIBA, Ltd
Bio-Rad Laboratories, Inc
Bruker Corporation
General Electric (G.E.)
Waters Corporation Becton
Dickinson and Company
Caprion Biosciences, and others.

Key Highlights -

The
global proteomics market was valued at USD
26,590.5
million in 2021. It is expected to reach USD
76,753.6
million by 2030, growing at a CAGR of
12.5% during the forecast period (2022–2030).
The
global
Proteomics
market has been categorized into reagents, instruments, and services based on the component. The reagents segment was the highest contributor to the market, growing at a CAGR of 11.9% during the forecast period.
The
global
Proteomics
market has been categorized into drug discovery, disease diagnosis, and others based on the application. The drug discovery segment was the highest contributor to the market, growing at a CAGR of 12.1% during the forecast period.
North America is the highest revenue contributor growing with a CAGR of 11.1% during the forecast period.

Market News

Jun 2022, Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union

Global Proteomics Market: Segmentation
By Component

Microarray
Spectrometry
X-ray Crystallography
Chromatography
Electrophoresis
Surface Plasmon Resonance
Microarray
Spectroscopy
X-ray Crystallography
Chromatography
Electrophoresis
Immunoassay

By Application

Drug Discovery
Disease Diagnosis

By Region

North America
Europe
Asia-Pacific
LAMEA

MENAFN11072024004597010339ID1108430234